The aim of this study was to discover new cyclic peptide ligands that selectively bind to both EGFR and EGFRvIII and evaluate the targeting cytotoxicity of their PDCs bearing the topoisomerase I inhibitor camptothecin (CPT) for NSCLC and glioblastoma cell lines. This evidence concerns the gene EGFR and glioblastoma.